Public health economics: a systematic review of guidance for the economic evaluation of public health interventions and discussion of key methodological issues by Edwards, R.T. et al.
  
 
P
R
IF
Y
S
G
O
L
 B
A
N
G
O
R
 /
 B
A
N
G
O
R
 U
N
IV
E
R
S
IT
Y
 
 
Public health economics: a systematic review of guidance for the
economic evaluation of public health interventions and discussion of key
methodological issues
Edwards, R.T.; Charles, J.M.; Lloyd-Williams, H.
BMC Public Health
DOI:
10.1186/1471-2458-13-1001
Published: 24/10/2013
Publisher's PDF, also known as Version of record
Cyswllt i'r cyhoeddiad / Link to publication
Dyfyniad o'r fersiwn a gyhoeddwyd / Citation for published version (APA):
Edwards, R. T., Charles, J. M., & Lloyd-Williams, H. (2013). Public health economics: a
systematic review of guidance for the economic evaluation of public health interventions and
discussion of key methodological issues. BMC Public Health, 13, 1001.
https://doi.org/10.1186/1471-2458-13-1001
Hawliau Cyffredinol / General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or
other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal
requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private
study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to
the work immediately and investigate your claim.
 22. Jun. 2020
Edwards et al. BMC Public Health 2013, 13:1001
http://www.biomedcentral.com/1471-2458/13/1001RESEARCH ARTICLE Open AccessPublic health economics: a systematic review of
guidance for the economic evaluation of public
health interventions and discussion of key
methodological issues
Rhiannon Tudor Edwards*, Joanna Mary Charles and Huw Lloyd-WilliamsAbstract
Background: If Public Health is the science and art of how society collectively aims to improve health, and reduce
inequalities in health, then Public Health Economics is the science and art of supporting decision making as to how
society can use its available resources to best meet these objectives and minimise opportunity cost. A systematic
review of published guidance for the economic evaluation of public health interventions within this broad public
policy paradigm was conducted.
Methods: Electronic databases and organisation websites were searched using a 22 year time horizon (1990–2012).
References of papers were hand searched for additional papers for inclusion. Government reports or peer-reviewed
published papers were included if they; referred to the methods of economic evaluation of public health
interventions, identified key challenges of conducting economic evaluations of public health interventions or made
recommendations for conducting economic evaluations of public health interventions. Guidance was divided into
three categories UK guidance, international guidance and observations or guidance provided by individual
commentators in the field of public health economics. An assessment of the theoretical frameworks underpinning
the guidance was made and served as a rationale for categorising the papers.
Results: We identified 5 international guidance documents, 7 UK guidance documents and 4 documents by
individual commentators. The papers reviewed identify the main methodological challenges that face analysts
when conducting such evaluations. There is a consensus within the guidance that wider social and environmental
costs and benefits should be looked at due to the complex nature of public health. This was reflected in the
theoretical underpinning as the majority of guidance was categorised as extra-welfarist.
Conclusions: In this novel review we argue that health economics may have come full circle from its roots in
broad public policy economics. We may find it useful to think in this broader paradigm with respect to public
health economics. We offer a 12 point checklist to support government, NHS commissioners and individual health
economists in their consideration of economic evaluation methodology with respect to the additional challenges of
applying health economics to public health.
Keywords: Health economics, Public health, Published guidelines, Public sector policy, Inequalities in health,
Outcome measurement* Correspondence: r.t.edwards@bangor.ac.uk
Centre for Health Economics and Medicines Evaluation, Institute of Medical
and Social Care Research, Bangor University, Dean Street Building, Bangor,
Gwynedd LL57 1UT, UK
© 2013 Edwards et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Edwards et al. BMC Public Health 2013, 13:1001 Page 2 of 13
http://www.biomedcentral.com/1471-2458/13/1001Background
We live in an unequal world and know that inequalities
in health and lifetime opportunity are fundamentally
linked to inequalities in income. A paradox is emerging–
in order to affect health gain in those groups of society
that face most socioeconomic challenges, we must trade
off our more familiar, if implicit, Western goal of health
gain maximisation. In the UK the principle of health
gain maximisation underpins the technical appraisal ap-
proach taken by the National Institute of Health and
Care Excellence (NICE), [1]. NICE updated its “Guide to
the methods of technology appraisal” in 2013 [2]. The
updated version does not appropriate directly to public
health; however, the guide maintains its position from
the previous version with regards to economic evalua-
tions. The use of cost-effectiveness, especially cost-utility
analysis is preferred [2]. Cost per Quality Adjusted Life
Year (QALY) estimates are favoured and appraised in ac-
cordance with the £20,000-30,000 threshold [2]. This is
justified by the institute’s focus on maximising health
gains [2]. In health economics, three papers have begun
to shape thinking about public health economics. Kelly
et al. [3] set out additional challenges of applying tools
of economic evaluation to public health interventions as
compared with the evaluation of clinical interventions.
These challenges span multiple versus single outcomes,
the effect of individual behaviour change upon the success-
ful uptake of interventions, the difficulty in establishing
cause and effect due to the multi-faceted nature of public
health interventions and the high level of social variation
involved in public health interventions. Weatherly et al. [4]
offered additional considerations that health economists
should build into their evaluations of public health inter-
ventions. These considerations being the need for other
approaches due to the limited availability of randomised
controlled trials, measurement of a range of outcomes be-
yond Quality Adjusted Life Years (QALYs), consideration
of inter-sectoral costs and consequences which may in-
clude wider benefits and spill over effects, and a focus on
equity. Payne et al. [5], introduced the idea of some public
health interventions having the characteristics of “com-
plex” interventions, and the subsequent need to measure a
much broader range of outcomes than focus on QALYs,
suggesting that capability theory may offer one way for-
ward as a means for better capturing such wider benefits
[6]. These three papers focus on, and critique, the trad-
itional toolbox of methods of economic evaluation applied
to the evaluation of Public Health interventions [7].
Looking back, in the UK, Derek Wanless challenged health
economists to apply their methods of economic evaluation
in a public health setting [8]. More recently, the NICE
Centre for Public Health Excellence has called for health
economists to think more broadly about how economics
as a parent discipline in its widest sense, can help supportthose responsible for resource allocation decisions in Pub-
lic Health. This was taken forward in a Medical Research
Council (MRC) Population Health Sciences Research Net-
work (PHSRN) funded workshop on population health
economics in Glasgow, May 2012. Though consensus
seems to be from the authors above, that the QALY is in-
adequate in a public health setting; Owen et al. [9] provide
a powerful message that many public health interventions
are indeed cost-effective, well below the NICE threshold of
£20,000-30,000 per QALY. We observe a growing interest
and expectation that public health interventions should be
“cost saving” [10], hence an interest by government, local
government and the NHS in return on investment analysis
as an alternative to cost-effectiveness analysis [11].
However, economic evaluations of public health eco-
nomics are not without challenges; therefore, there is a
need of guidance in this field. To examine what guidance
currently exists in the field of economic evaluations of
public health economics we conducted a systematic re-
view of UK guidance, international guidance and searched
for papers offering observations from key commentators
of the economic evaluation of public health interventions.
Methods
Literature search
We followed a PRISMA [12] approach to reporting the
findings of the systematic review of published guidance for
the economic evaluation of public health interventions.
PubMed, MedLine, CRD database, EconLit were searched
between September and October 2012 for published guid-
ance of economic evaluation methods for public health
interventions. In addition, The Medical Research Council,
Joseph Rowntree Foundation, National Institute for Health
and Clinical Excellence, World Health Organisation and
World Bank websites were also searched for relevant guid-
ance and reference lists of published reviews were scruti-
nized (e.g. Owen et al. [9]).
Databases were searched for literature for the period
1990–2012. It was deemed appropriate to narrow the
search to this time period as we wanted to include the
more recent contributions and the studies found did not
generally refer to articles before 1990. We restricted our
search to papers published in the English language.
Searches were conducted in October 2012.
The search terms used were: public health, public health
economics, guidance for economic/econometric evalu-
ation of public health interventions, challenges of public
health economics, methods of public health economics,
world health organisation, and health economics [see
Additional file 1].
Study selection
The following exclusion and inclusion criteria were
employed during the searches.
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 The paper had a reference in the title and/or
abstract to the methods of economic evaluation of
public health interventions.
 The paper identified key challenges of conducting
economic evaluations of public health interventions.
 The paper made recommendations for conducting
economic evaluations of public health interventions.
 The paper was from a national source (e.g.
Government or Advisory Group policy documents
and reports) or published in a peer-review journal.
Papers were excluded if;
 They were not specifically related to the economic
evaluation of public health interventions.
 They did not provide guidance on the economic
evaluation of public health interventions.
 They were published in a language other than
English.
Papers identified by the searches were screened by
reading the abstracts. Articles that matched the inclu-
sion criteria above were obtained and read by RTE,
JMC and HLW. It was also necessary to search litera-
ture by hand e.g., lists of references of guidance meeting
the inclusion criteria. Information was extracted from
each paper on the challenges and recommendations of
methods to employ when conducting economic evalua-
tions of public health interventions. We wanted to look
as widely as possible at relevant health economics spe-
cific and public policy guidance on the evaluation of
public health interventions.
Data collection process
We developed a summary of guidance and key observa-
tions, providing the following information; author, publi-
cation date, source of published guidance (e.g., UK or
International) and key points. As this review was under-
taken in a public policy context with reports the more
prominent type of published guidance the authors were
unable to adhere to PICO guidelines, instead we pro-
vided a summary.
Results will be presented as a narrative review as the
search strategy aims to identify UK and international guid-
ance and observations from key commentators. Therefore,
results are likely to contain a high level of heterogeneity,
which may not permit meta-analysis.
Assessment of theoretical underpinning
To strengthen the narrative review an assessment will be
made of the theoretical underpinning of the included
guidance. The theoretical paradigms will be categorisedbased upon whether they related to a macro/micro [13],
welfarist/extra welfarist [14], capabilities [15] or behav-
ioural economics approach [16]. These theoretical un-
derpinnings will serve as a rationale or framework for
categorising the papers. It must be noted however that
no specific mention was made in the guidance as to its
theoretical basis, but rather it is a judgment that we the
authors have made. The first paradigm delineates be-
tween macro and micro economics. It is suggested that
if a set of guidance relates to the evaluation of individual
programmes then it belongs in a micro framework [13].
Otherwise if the guidance looks at outcomes on a popu-
lation, whole economy level then a macro framework
would apply [13]. Research on macroeconomic modelling
uses information fed into general equilibrium models
which connect health expenditure growth to its impact on
the overall economy [17]. Health impact assessments
conducted by the World Bank can be said to have a strong
macro basis. Further a differentiation is made based on
whether the theoretical underpinnings of the guidance re-
lates to welfarist or extra-welfarist theory. Welfarism re-
lates to the assumption that it is a measure of utility that’s
important when measuring health, that is the utility re-
ceived from the consumption of healthcare goods and ser-
vices relative to other goods and services [14]. It is based
on individualism and consequentialism [18]. Cost-benefit
analysis is a good example of a welfarist perspective [19].
Extra-welfarism on the other hand goes beyond the study
of utility and takes health itself and other non-utility mea-
sures as the unit of outcome [14]. Extra-welfarism is based
on the underlying idea that rational choice and utility
maximising behaviour, the underpinnings of welfarist the-
ory are irrelevant to health behaviours [18]. Health is the
maxim and not welfare. The EQ-5D [20] and concurrent
measurement of QALYs provide a good example of
extra-welfarist thinking). The third type of theoretical
basis for guidance is the capability approach. Capabilities,
according to Sen [15], are concerned with the ability to
achieve functionings such as attachment, role, enjoyment,
security and control. Ill health does not reduce quality of
life on its own but insofar as it reduces the ability to
achieve, for example, independence [21]. We assess the
guidance based upon whether or not it promotes the cap-
ability approach [15] in a robust way, as an alternative to
the QALY approach [5]. Finally, an underlying theory
based on behavioural economics studies the behavioural
aspects of economic agents and how this affects their de-
cision making [16]. Behavioural economics does not sug-
gest a rejection of the neoclassical approach to economics,
but does advocate the psychological underpinnings of eco-
nomic analysis. In this way it is argued that the assump-
tions that underlie theory are adapted to reflect a more
realistic view of the world. Here we assess whether or not
the guidance is based in behavioural economic theory.
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The initial database search provided a total of 36 cita-
tions. 36 remained after removing duplicates. Of these,
13 were excluded based upon their executive summary
or abstract as they did not meet the criteria. Of the
remaining 23, a total of 16 papers met the inclusion cri-
teria (See Figure 1).
Due to the heterogeneity of the results yielded by the
search, we provide a narrative review below. Guidance
relevant to the economic evaluation of public health in-
terventions was divided into the following categories;
UK guidance, international guidance and observations of
key commentators relevant to the economic evaluation
of public health interventions.
Guidance relevant to the economic evaluation of public
health interventions
UK guidance
Looking beyond the health economics literature to broad
economic and public policy guidance, which may be dir-
ectly relevant to the evaluation of public health interven-
tions, the HM Treasury Green Book [22] outlines various
points related to the treatment of costs and benefits when
conducting economic appraisals of public programmes,
points which relate well to the area of public health.
According to the Green Book guidance, relevant costs and
benefits, i.e. those which can be attributed or influenced 
 
Potentially relevant references = 36 
 
 
Relevant references= 23 
 
 
Articles meeting inclusion criteria 
and therefore included in the 
review = 16 
Figure 1 Flowchart outlining paper selection process for the systemaby the intervention in question should be measured and
then valued and care should be taken to avoid spuriously
accurate figures [22]. Costs and benefits should be based
on market prices as these are usually the best reflection of
their opportunity cost i.e. best alternative use [22]. Wider
social and environmental costs and benefits should be
considered although there may not be a market price for
these costs and benefits. However, they should not be ig-
nored simply because it is difficult to quantify them.
When it is not possible to express costs and benefits
in market prices the ‘willingness to accept measure’
should be used [22]. This is where patients state the
minimum amount they would need to be compensated
in order to forgo a good or service. In terms of valuing
benefits the preferred measure is also market prices unless
the market is distorted and does not reflect truly oppor-
tunity costs of resource use. If this is the case techniques
such as ‘willingness to pay’ surveys can be used or one can
infer a price from consumer behaviour through their ‘re-
vealed preference’.
The Joseph Rowntree Foundation [23] has published a
practical guide to conducting economic evaluation in
the social welfare field but many of the principles can be
applied to the evaluation of public health interventions.
Although the study excludes health care it draws heavily
upon health economics to address questions in the social
welfare field. Examples of health care economic evaluationReferences excluded at 
abstract screening stage = 
13 
Articles in languages other 
than English and therefore 
excluded = 0 
Articles that did not meet 
the inclusion criteria and 
therefore excluded = 7 
tic review.
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applying these methods in a social welfare context. There
is a stronger focus on the evaluation of complex public
health interventions which, according to the authors, have
much more in common with the social welfare field. They
outline the main methods of economic evaluation before
going on to discuss methods of evaluating specific costs
and benefits of different types of interventions. By provid-
ing information on how to synthesise costs and benefits
they arm the reader with the necessary tools to conduct
cost-effectiveness analysis.
A set of guidance has been put forward by Drummond
et al. [7]. In this they acknowledge the additional chal-
lenges of applying traditional techniques of economic
evaluation to a public health context over and above that
of a clinical context. They add that a study by Tarn and
Smith [24] concludes that there is widespread agreement
on the main methods of economic evaluation of clinical
interventions, whilst there is still some disagreement
over specific methodological issues relating to public
health. Drummond et al. [7], reiterated in Weatherly
et al. [4], discussed below, identify four specific meth-
odological challenges in economic evaluation of public
health interventions:
Firstly, attributing outcomes to interventions; most
published guidelines, including NICE, prefer the use of
Randomised Controlled Trials (RCTs) to compare alter-
natives [1,2]. There are likely to be fewer controlled tri-
als of public health programmes due to the very large
sample size required to power pragmatic trials of public
health interventions adequately. Follow up in clinical
trials is often limited to one or two years at the most,
whilst public health programmes could be expected to
have an impact over the longer term. Secondly, measur-
ing and valuing outcomes; in economic evaluations of
clinical interventions, outcomes are usually measured in
natural units or QALYs [1,2]. In the economic evaluation
of public health interventions, other outcomes must be
considered including effects on individuals not directly
targeted by the programme and non-health related out-
comes such as education. Some of these outcomes can
be incorporated into QALYs, some not. Thirdly, incorpor-
ating equity considerations; in many cases the aim of the
public health intervention is to reduce inequalities. The
normal assumption in economic evaluation methods is
that a QALY is of the same value to everyone who re-
ceives it. It is possible to look at the distribution of
QALY gains between population sub-groups in order to
tackle inequalities in health. Fourth, identifying inter-
sectoral costs and consequences; the impact of public
health interventions can be wide-ranging. The costs and
benefits may fall on parts of the public sector not con-
fined to health alone, such as the judicial system, educa-
tion and housing.The main guidance for the UK is set out by NICE in
its 2009 document “Methods for the development of
NICE public health guidance” [25]. This guidance out-
lines the conditions under which an economic analysis
should be carried out. If a high-quality economic study
has already been published which relates to the public
health intervention under consideration then no further
economic modelling should be attempted. However, when
there is paucity of evidence in the literature and when
there is expected net benefit from a public health interven-
tion then the guidance indicates that we should proceed
with economic evaluation. This guidance is underpinned
by an extra-welfarist approach in that, it builds on and
adapts NICE guidance for the appraisal of health care tech-
nologies [1,2], adhering to the assumption that the aim of
public health interventions is to maximise QALYs. Al-
though NICE have not explicitly recommended an ICER
above which public health interventions should not be
recommended and below which they should, in general,
interventions with an ICER of less than £20,000 per QALY
gained are considered cost-effective [25].
The Cabinet Office has published guidance on ‘Social
Return on Investment’ (SROI) in public sector settings
but the techniques suggested relate well to the area of
public health [11]. Social Return on Investment is a
method used to capture value beyond that of financial
return. There are two types, evaluative and forecast.
Forecast is potentially useful in the planning stage of an
intervention and may show how investment could maxi-
mise impact, while evaluative SROI is retrospective. In
terms of measuring costs and outcomes, this may be
done using market prices. The price mechanism is an al-
locative concept that relates the relative valuations of a
good or service by two parties. Where a cost or outcome
can be measured using price there is enough informa-
tion contained within that price to enable a transaction
to take place where both parties maximise the benefits
from the transaction. However when it is not possible to
measure costs and outcomes using price, other methods
have to be considered. Here the authors discuss such
valuation methods, which include ‘contingent valuation’,
that is the individual’s ‘willingness to pay’ (benefits) or
‘willingness to accept’ (costs) and ‘revealed preference’.
After identifying and measuring the relevant costs and
benefits an SROI ratio can in theory be calculated as the
total present value divided by the value of inputs which
gives a ratio of £x value per £1 of investment. Of course
the challenge of placing monetary value on public health
outcomes is not to be underestimated. It may or may
not be more straightforward than in the economic evalu-
ation of a clinical intervention, as wider impacts spilling
over across sectors may in fact have market prices.
In addition to the NICE guidance referred to above
there is another set of guidance published by NICE
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vestment of public health interventions [26]. This ap-
proach aims to measure the potential savings that can be
achieved by implementing one intervention over an-
other. The team provide tools for financial planning,
over a 3–5 year time horizon to support local implemen-
tation of NICE’s recommendations. One of the main
steps in the cost impact assessment is assessing inter-
ventions and identifying areas that are most likely to
have a resource impact. In addition to costs of delivering
services the potential savings arising from recommenda-
tions are also estimated.
In terms of the theoretical paradigms underlying UK
guidance we found the majority of the guidance was
classed as extra-welfarist. This guidance discussed going
beyond QALYs to measure wider costs and benefits. The
guidance by the Cabinet Office on SROI was guided by a
micro-economic theory in that it discussed one-by-one
evaluations and no attempt was made to aggregate re-
sults into a macro framework.
See Table 1 for a summary of the UK guidance above.
International guidance
We found a range of published guidance on applying
economic evaluation methods to public health interven-
tions from international organisations. For example the
World Bank guidance [27] is focused on using tech-
niques of economic evaluation to select a cost-effective
package of healthcare interventions in developing coun-
tries. Total healthcare costs are expected to rise in the
future due to the ageing population needing more hos-
pital and long term care. This has implications for the fi-
nancing and organisation of health services. The need
for economic analysis of public health interventions has
therefore never been greater. This manual provides guide-
lines for health planners on how to collect, analyse and in-
terpret cost and effectiveness data to evaluate a package of
health services. It cannot however take into account the
inherent differences between countries in terms of differ-
ent health care systems having different features and so it
recommends that the approach be customised in order to
accommodate country specific studies.
The World Health Organisation (WHO) [28] who ad-
vocate use of a generalised cost-effectiveness analysis ap-
proach, where the comparator is “doing nothing”, as
opposed to the “usual care” allowing decision makers to
see what could be achieved if all health care resources
were re-allocated. So instead of advocating an “incre-
mental” approach to evaluation, the WHO approach en-
courages analysis of a portfolio of interventions to see
whether they provide an efficient use of resources. The
WHO guidance focuses on the need to be able to gener-
alise results across different international settings. They
argue that generalised cost-effectiveness analysis can beused for a wide range of health technologies, including
public health interventions.
Honeycutt et al. [29] provide guidance from the US
which takes the form of a practical ‘step-by-step’ guide
to conducting cost-effectiveness analyses of public health
interventions. It begins by identifying the study question
which is essential in order to know what costs and bene-
fits to include and what kind of methods to employ. The
guidance goes on to identify the study perspective, that
is, from whose perspective is the study based? It distin-
guishes between a societal perspective, where all costs
and benefits are considered even if no actual payment is
made for some of these resources, and a narrower stake-
holder perspective. The next step is to consider the time
frame for the intervention. They argue that this is
straightforward for initiatives that involve one-on-one
contact over the course of, say, a year but more difficult
if we are considering such interventions as media cam-
paigns for example. The last step in the process is to
choose the relevant method of economic evaluation.
They list the different types of economic evaluation and
suggest the context in which each should be applied. For
example, cost analysis can be useful for choosing alter-
native resource mixtures that limit programme costs.
Cost-effectiveness analysis answers questions about
whether interventions produce outcomes that are worth
the investment and should be used when comparing two
or more strategies.
According to the WHO a Disability Adjusted Life Year
(DALY) is a measurement of a year of ‘healthy’ life lost
due to disease or premature death, or lived at a lower
quality due to a disability or disease [28]. However, DALYs
only reflect the presence of a medical condition which re-
lates to certain functional limitations and do not give
credit to interventions that improve the ability of individ-
uals to live with a certain disability or disease. The WHO
proposes to address this gap in the DALY approach by
offering two public health relevant outcome measures 1)
the activity limitation score and 2) participation limitation
score, based on data from Zambia (Mont and Loeb [30]).
The Organisation for Economic Co-operation and De-
velopment (OECD) [31] has produced guidance which
aims to give an economic framework to the prevention
of chronic diseases. Their premise is that the prevention
of chronic diseases may increase social welfare and en-
hance health equity. Their approach links chronic disease,
caused mainly by lifestyle choices, with the performance
of markets and rationality failures. Priority is given to
areas of potential failure such as externalities, with the ef-
fects of individual consumption of tobacco, for example,
having an effect on others (negative externality) thus justi-
fying interventions. Information failure is another type of
market failure whereby individuals lack sufficient know-
ledge on what constitutes an overall healthy diet for
Table 1 Summary of UK published guidance
Source of published
guidance
Key points Theoretical paradigm underpinning guidance
HM Treasury Green Book
(2003) [22]
Care should be taken to avoid spuriously accurate
figures; costs and benefits should be based on
market prices where possible; where not possible
techniques such as ‘willingness to accept’ (for costs)
and ‘willingness to pay’ (for benefits) should be
used; wider social and environmental costs should
be considered; use previous studies to capture
value of benefits (‘benefit transfer method’).
The approach used here is a welfarist based
approach whereby outcomes relate to a notion of
utility.
Joseph Rowntree Foundation
(Byford et al. 2003) [23]
This is a practical guide to conducting economic
evaluation in the social welfare field, but many of
the principles can be applied to public health
interventions. There is guidance on how to
measure costs and benefits along with a standard
assessment of the different types of cost-
effectiveness techniques (e.g., cost-effectiveness,
cost-utility, cost-benefit etc.).
A welfarist approach is the theoretical underpinning
here. There is no discourse as to the measuring of
wider costs and benefits.
Public Health Research
Consortium (Drummond
et al., 2006) [7]
Acknowledges additional challenges of applying
traditional techniques of economic evaluation to a
public health context. Undertook a methodological
review of main challenges and proposed some
solutions (underpins Weatherly et al. 2009) i.e.
breadth of costs and benefits; need to consider
effect on inequalities in health; attribution of costs
and outcomes to stakeholders; measuring and
valuing outcomes across different sectors.
An extra-welfarist approach is taken here where
outcomes are not confined to a welfarist utility
framework, but rather a specific importance is put
upon measuring wider costs and benefits which are
wider than QALYs.
MRC Guidance on
developing and evaluating
complex interventions (2008)
[32]
Defines complex interventions as “interventions
with several interacting components”. Many public
health interventions can be described as complex
in this sense. Provides a frame work ranging from
feasibility, evaluating (including assessing cost
effectiveness), implementation and development.
Economic evaluation is not dealt with specifically in
this guidance which is focused on effectiveness.
There is no underlying theory here in terms of
economics as the guidance is mainly concerned
with effectiveness rather than cost effectiveness, as
found in the evidence based medical movement.
NICE Public Health Guidance
(2009) [25]
Economic evaluation only relevant if there is
expected net benefit, taking into account number
of individuals affected; uncertainty in the cost-
effectiveness literature and the likelihood that
economic analysis will clarify matters. Economic
evaluation is not needed if: it is not possible to
estimate costs and benefits; if it is obvious the
resources required are modest in comparison to
health gains and if robust economic evaluation is
already available. Assumes that objective of public
health interventions is to maximise QALY. Cost per
QALY calculations recommended using a £20,000-
30,000 threshold. Also cost-consequence or cost-
benefit analyses recommended.
This guidance is based on a conceptual framework
for public health which comprises four vectors–
population, environment, society and organisations
all of which affect human behaviour. An extra-
welfarist approach is taken whereby QALYs are
viewed from an extra-welfarist perspective.
Cabinet Office Social Return
on Investment Guide (2010)
[11]
There are two types of SROIs: evaluative and
forecast; assigning a value to things that do not
have a market price: contingent valuation–
willingness to pay or accept compensation,
revealed preference–hedonic pricing and average
household spending–from sources such as the
Family Spending Survey; SROI ratio is calculated as
the total present value divided by the value of
inputs–this gives a ratio of £x of value per £1 of
investment; sensitivity analysis needs to be carried
out–by how much would the parameters need to
be changed to get an SROI of £1:£1.
SROI analysis has a microeconomic theoretical
underpinning whereby evaluation of specific
interventions is done on a one-by-one basis and no
attempt is made to aggregate the results into a
macro framework.
NICE guidance for assessing
cost effectiveness and ROI
(2011) [26]
A cost impact project set up by NICE in 2010. The
aim is to meet public sector demands to
demonstrate potential returns on investment of
public health interventions. It produces tools for
financial planning to support local implementation
Wider costs and benefits are considered here rather
than concentrating on QALYs alone. Insofar as this
is true it could be said that an extra-welfarist
theoretical approach has been taken.
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Table 1 Summary of UK published guidance (Continued)
of NICE’s recommendations. This report assesses the
literature in terms of cost-effectiveness analyses and
their adherence to NICE guidelines. They provide a
number of recommendations to changes to NICE’s
methods and processes.
Summary of UK published guidance relevant to the economic evaluation of public health interventions.
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http://www.biomedcentral.com/1471-2458/13/1001example. Rationality itself, the underpinning of well-
functioning markets, can be said to have failed. They
argue that this is the case when inconsistent time-
preferences and lack of self-control lead to addictive be-
haviour thus making lifestyle changes difficult. The
OECD suggests influencing choices available to individ-
uals and seeks preventative measures where these mar-
ket failures exist.
In terms of a theoretical paradigm all international
guidance was classed as extra-welfarist, apart from the
OECD (2008) which looked at the problem from a vant-
age of behavioural economics. The majority of guidance
advocated cost-effectiveness analysis, whilst Mont and
Loeb [30] proposed the use of DALYs rather than mor-
tality on its own.
See Table 2 for a summary of the international guid-
ance above.Table 2 Summary of international published guidance
Source of published guidance Key points
World Bank (1993) [27] The World Bank produced guidance
using techniques of economic eval
a cost-effective package of healthca
in developing countries.
World Health Organisation (2003)
[28]
The World Health Organisation adv
generalised cost-effectiveness analy
where the comparator is ‘doing no
opposed to the more conventional
Honeycutt et al. (2006) [29] A practical ‘step-by-step’ guide to c
effectiveness analyses of public hea
These steps include defining the stu
identifying the study perspective, d
time frame and analytic time period
the type of economic study to con
Mont and Loeb (2008) [30] Beyond
DALYs: developing indicators to
assess the impact of public health
interventions on the lives of people
with disabilities.
Aims to address a gap in the DALY
offering two public health relevant
measures 1) Activity limitation score
limitation score, based on data from
OECD (2008) [31] The prevention of
lifestyle related chronic diseases: an
economic framework.
Focuses on the premise that preven
disease may increase social welfare
health equity. This approach links c
the performance of markets and ra
preventing individuals achieving th
outcomes. Focused on influencing
to individuals and seeking preventa
where market failures exist.
Summary of international published guidance relevant to the economic evaluationObservations of key commentators relevant to the
economic evaluation of public health interventions
There have been a few publications that discuss the
methodology of economic evaluations of public health
interventions, most notably Kelly et al. [3], Weatherly
et al. [4] and Payne et al. [5]. Kelly et al. [3] set out seven
ways in which the economic evaluation of public health
interventions is potentially different from the evaluation
of clinical interventions. Among these is the fact that,
firstly, unlike clinical interventions most public health
interventions require a change in individual or popula-
tion behaviour in order to ensure uptake of the interven-
tion in the first place. This behavioural change must be
modelled into the economic analysis. Another problem
concerns biological and social variation, in that clinical
trials are conducted in a narrowly defined area and within
a known span of biological variation. Public healthTheoretical paradigm underpinning guidance
focused on
uation to select
re interventions
The authors here write from the perspective of
extra-welfarism, as they promote the use of cost-
effectiveness analysis in their study.
ocate use of a
sis approach,
thing’, as
‘usual practice’.
The authors here write from the perspective of
extra-welfarism as they promote the use of cost-
effectiveness analysis in their study although they
propose an alternative approach in terms of a
generalised cost-effectiveness analysis.
onducting cost-
lth interventions.
dy question,
etermining the
and selecting
duct.
The authors focus on cost-effectiveness analysis and
so it can be said that the theoretical underpinning
here is extra-welfarism.
approach by
outcome
2) participation
Zambia.
The theoretical underpinning here is extra-welfarist
since the report is concerned with improving
health outcomes by using DALYs rather than
mortality on its own.
tion of chronic
and enhance
hronic disease to
tionality failures,
e best possible
choices available
tive mechanisms
This approach is based on a behavioural economics
theoretical framework focusing on rationality and
market failure.
of public health interventions.
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socio-economic context which is not as easily defined or
as generalisable. Finally, public health interventions can
change during their implementation which can complicate
the interpretation of results. This is because public health
interventions are usually implemented without any pre-
trial development and are thus susceptible to change dur-
ing their implementation.
Weatherly et al. [4] suggest four key methodological
challenges that face the economic analyst when conducting
evaluations of public health interventions. These comprise
firstly, the problem of attributing effects to a specific public
health intervention and the fact that there will inevitably
be less use of randomised controlled trials in the analysis
of public health programmes due to power and sample size
requirements. Secondly, measuring and valuing outcomes;
QALYs may not be the best way to measure effects of
individuals not targeted by the intervention and other non-
health effects. Thirdly, equity considerations; i.e. it is pos-
sible to look at the distribution of QALY gains between
population sub-groups, but that there will be a trade off or
sacrifice of moving from an efficiency goal of overall QALY
maximisation. Fourth, inter-sectoral costs and conse-
quences; costs and benefits may fall on parts of the public
sector not confined to health alone.
Payne et al. [5] distinguish between ‘simple’ and ‘com-
plex’ interventions by recourse to the 2008 MRC guid-
ance [32]. Accordingly complex interventions have the
properties of involving; more than one group or organ-
isational level that is targeted by the intervention, nu-
merous and variable outcomes and a degree of flexibility
or tailoring of the intervention being permitted. They do
not talk specifically about public health interventions al-
though these can also be deemed as complex. Rather the
authors discuss complex interventions in the context of
genetic services. These are regarded as similar to other
types of complex interventions in that they take into ac-
count non-health outcomes as well as health related out-
comes. The aim of this paper is two-fold. Payne et al. [5]
seek to understand if it is reasonable to measure health
status alone in the context of complex interventions.
They come to the conclusion that public health guidance
is more pragmatic than for clinical interventions and
should include alternative outcome measures, such as
life-years gained and cases averted, as well as QALYs.
Therefore, maximising QALY gains should not be the
only aim of complex/public interventions. It should also
be looking at Sen’s capability theory [15] as a possible
component of outcome measures. In so far as the cap-
ability approach (defined as the ability to function given
the choice) looks to distribute capability equally across
society this is fundamentally different to the idea of
maximising QALYs with no regard to equity issues. Sec-
ondly, the authors aim to find out if it is possible toevaluate complex interventions using the current NICE
guidelines. They conclude that outcome measures asso-
ciated with a complex intervention need to be extended
to include; the values of the process of delivering
healthcare, non-health outcomes and capability (first
proposed by Sen, [15]) to participate equally in life [33].
All these are relevant arguments to how best we ap-
proach the evaluation of public health interventions.
Marsh et al. [34] concede that economic evaluation
methods developed for Health Technology Assessments
(technical interventions), do not capture all the costs
and benefits associated with public health interventions.
They argue that the trend of using modelling techniques,
and specifically a broad range of outcomes, to assess
public health interventions should continue. They argue
for the development of a number of ‘valuation paradigms’
such as Sen’s capability approach [15] and ‘subjective well-
being’ approach [35] both of which can provide the deci-
sion maker with broader measures of value than the
approaches currently on offer.
Apart from the capability approach employed in Payne
et al. [5] most of the documents from key commentators
are underpinned by extra-welfarism. The majority of key
commentators in this field see the need and importance
to go beyond a utility measure of health, and this theme
is recurrent in the literature.
See Table 3 for a summary of observation by the key
commentators.
Discussion
This systematic review yielded a total of 16 relevant pa-
pers. A paucity of material is therefore apparent in this
field, especially if we compare with the economic evalu-
ation of clinical interventions. Economic evaluations of
public health interventions can be seen as a nascent
academic endeavour, but the literature does identify the
major methodological challenges that analysts will face
when conducting such evaluations.
The main theme, reflected throughout, concerns the
holistic nature of public health interventions. That is,
complex public health interventions, by their very nature,
deal with wider social and environmental costs and bene-
fits than do clinical interventions and therefore there is a
need to consider a much broader range of outcomes than
a focus on QALYs alone [3-5,11,22,23]. This is reflected in
the common theme of extra-welfarism that underpins the
majority of guidance found in the review. Another salient
issue identified remains on the theme of QALYs. It is ap-
parent, from the literature [4,5], that the efficiency goal of
overall QALY maximisation is not sufficient in the realms
of public health interventions. The reasons for this are
two-fold. First public health interventions must deal with
equity considerations–a theme which is recurrent in the
literature. Insofar as this is true there is a trade-off
Table 3 Summary of suggestions from key health economics commentators
Source of published
guidance
Key points Theoretical paradigm underpinning guidance
Kelly et al. (2005) [3] Limited evidence of what interventions will work to reduce
inequalities in health; evaluating single initiatives may fail
to capture effects that rely on multiple interventions;
behaviour needs to be changed in order to secure uptake
of the intervention; difficult to isolate cause and effect due
to multi-faceted nature of public health interventions;
biological variation in clinical trials are much narrower than
social variation in which public health interventions take
place; public health interventions can change during their
implementation; at what point is an intervention judged to
have succeeded?
As they advocate the use of cost-benefit analysis it could
be said that the authors come from a theoretical base of
welfarism.
Weatherly et al. (2009) [4] Attribution of effects: likely to be fewer controlled trials of
public health programmes–other approaches will be
necessary; measuring and valuing outcomes: other
outcomes, apart from QALYs, may be relevant e.g. external
outcomes not confined to the health sector alone;
identifying inter-sectoral costs and consequences: costs
and benefits may fall on many parts of the public sector;
incorporating equity considerations: in many cases the
main objective of the intervention is to reduce health
inequalities.
An extra-welfarist theoretical paradigm is used here in
terms of concentrating on measuring benefits not
adequately captured by QALYs.
Payne et al. (2012) [5] Valuation and Evaluation Research Theme (VERT)
demonstrates that complex public health interventions
have broader objectives than just health gain; maximising
health gain is not a sufficient objective to achieve once
cost and benefits outside the healthcare sector are
recognised; public health guidance is more pragmatic than
for clinical interventions and includes using alternative
outcome measures (e.g. life years gained, cases averted) as
well as QALYs; the authors suggest a move away from
defining health benefits in terms of utility or QALY
maximisation to consider non-health benefits and a
measure of capability (or empowerment).
A strong theoretical basis to this guidance is the
capability approach. This is coupled with an extra-
welfarist perspective where wider costs and benefits are
considered.
Marsh et al. (2012) [34] Reviews methods that could be employed to capture
wider range of benefits generated by public health
interventions; economists need to embrace a wider set of
modelling techniques to capture the effects of public
health interventions the selection of which should be
facilitated by the production of better data on behavioural
outcomes; more valuation paradigms should be explored
such as the capabilities and subjective well-being
approach.
The authors take an extra-welfarist perspective whereby
wider costs and benefits are considered along with a
wider range of modelling techniques. Behavioural
economics is also a key theoretical underpinning where
modelling of behavioural outcomes is considered.
Summary of suggestions by key commentators relevant to the economic evaluation of public health interventions.
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misation on one hand and equity issues that come to the
fore on the other. Indeed Payne et al. [5] suggest Sen’s
capability theory [15] as a means of including equity con-
siderations in economic analysis of public health interven-
tions since capability theory considers the distribution of
capability across society. Secondly as the public health
guidance is more pragmatic than is the case for clinical in-
terventions then alternative outcome measures such as
life-years gained and cases averted should be employed in
addition to QALYs. However, although the argument that
we should be looking beyond QALYs is indeed compelling
it should also be made clear that QALYs, and their com-
mon currency, do provide an useful way of deeming if
public health interventions are cost-effective in relation toNICE thresholds [9]–an argument that could be difficult
to make without them.
Health economics coming full circle
In the UK, health economics in the 1960s grew out of
more general public policy economics, responding to a
demand from the NHS to address resource allocation is-
sues within a culture of evidence based medicine [36,37].
In the 1990s and 2000s, health economics remained
within a “medical model” of healthcare [38-40], with a
focus on the standardisation of methods of evaluation [7].
However, paradigms were beginning to change with a
focus on “health economics” rather than health services
economics [41], which has continued through the decade,
with growing interest in how to apply techniques of
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terventions. Arguably this developed from the Wanless
2004 [8] report and a growing awareness of pressures on
the NHS attributable to lifestyle choices. Recent commen-
tators (Kelly et al. [3], Weatherly et al., [4] and Payne
et al., [5]) have argued for health economists to measure a
full range of outcome measures, going beyond QALYs;
take account of stakeholders, and to acknowledge poten-
tial impacts on the need to address inequalities in health.
We argue here that health economics may have come full
circle from its roots in broad public policy economics and
that we may find it useful to think in this broader para-
digm with respect to public health economics. Thinking
within a broader paradigm also applies to the theoretical
underpinnings of guidance within this field. The majority
of guidance found was categorised as extra-welfarist; how-
ever, we argue that perhaps this should be widened to in-
clude more than utility such as QALYs. It should include
capability theory, behavioural economics theory and in
some cases return full circle to more welfarist principles.
The QALY/SROI dilemma
There seems to be two schools of thought emerging in
the literature relating to the economic evaluation of public
health interventions. At this point it is worth restating that
public health spans the environment, public policy, con-
trol of infectious diseases, screening, supporting behaviour
change relating to consumption and lifestyle choices, and
supporting government regulation in order to foster a so-
ciety that promotes better health. There has been much
more literature on economic evaluations of public health
interventions aimed at the individual level than the poten-
tial much larger gains from environmental or legislativeTable 4 Checklist of considerations when considering publish
interventions
1 What is the appropriate theoretical framework for analysis e.g., welfarist,
2 What is the setting of the public health intervention under evaluation? (e
supporting behaviour change; supporting government legislation or pol
3 Is this best described as a primary, secondary or tertiary prevention inter
4 What is the main agency (government; health service; local government
stakeholders?
5 If this is an intervention aimed at behaviour change, what are the key le
architecture and nudging)?
6 What is the appropriate time horizon of analysis and what is the most ap
7 If the public health intervention aims to “shift the curve”, are we most in
8 How is this public health intervention likely to impact on inequalities in
9 Will subgroup analysis help identify the range of cost effectiveness estim
10 What are the main outcome measures of interest e.g. QALYs/DALYs or a
outcomes?
11 How important is it to value costs, benefits and returns in monetary term
short, medium or long term?
12 How relevant will it be to compare an ICER with the NICE threshold of £adaptation [42]. The extra-welfarist theoretical consensus
of the guidance seems to be that QALYs are inadequate as
a lone measure of outcome of public health interventions,
as they fail in any way to capture the potential broad range
of benefits to an individual, their family, community and
society as a whole. However, the benefits of using a com-
mon accepted currency such as the QALY are illustrated
by Owen et al. [9] who provide a powerful message that
many public health interventions are indeed cost effective,
well below the NICE threshold of £20,000-30,000 per
QALY. Without the use of QALYs this argument could
not be effectively put forward. Proponents of a SROI ap-
proach, which has its roots in welfarism, seem to have
brushed away the 40 years that health economists have
wrestled with assigning a monetary value to health out-
comes. Why should this be any easier in a public health
setting than in a clinical setting?
Should we expect public health interventions to be cost
saving?
The SROI approach perpetuates a growing expectation
in our experience that public health interventions “need”
to demonstrate that they will save money for society in
the long run. This is interesting as decisions to fund
surgical interventions or a new drug are not routinely
subjected to this expectation of “invest to save”. Woolf
et al. [10] in a US context, argue that there is a need to
distinguish between measuring the outcome of a public
health intervention e.g., the number of people who stop
smoking in response to a particular intervention, as op-
posed to the wider long term social benefits of reduced
prevalence of smoking in society and associated eco-
nomic benefits. Woolf et al. [10] argue that there is aed guidance for the economic evaluation of public health
extra-welfarist, capability theory?
.g., environmental change; infectious disease control; screening;
icy)
vention i.e. upstream or downstream?
; voluntary sector) responsible for implementation and who are the key
vers of change (legislation; price; changing social norms; choice
propriate discount rate for costs and outcomes?
terested in the centre or tails of the distribution?
health?
ates across different settings, delivery methods and population groups?
large range of outcome measures relating to health and wider social
s? Is it reasonable to expect the intervention to be cost saving in the
20,000-30,000 or an international equivalent?
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prevention intervention in the same way as a clinical
intervention–mindful that it may well have much wider
benefits, not just expect it to be cost saving, hence level-
ling the playing field for resources between public health
and clinical interventions.
Design conduct and reporting issues of economic
evaluations of public health interventions
The checklist below was inspired by the Drummond et al.
checklist for a sound economic evaluation [43] and our
own experiences of designing, undertaking and reporting
economic evaluations alongside trials of public health in-
terventions [44-47]. None of the guidance above, in our
view, answers these questions systematically, to this extent
our checklist is novel in distilling out key questions for
consideration. The sets of guidance reviewed in this paper
do provide a wide range of frameworks within which to
approach the whole task of conducting economic evalua-
tions of public health interventions. These questions, to-
gether with the sets of guidance reviewed in this paper
highlight issues that need addressing in the design con-
duct and reporting of economic evaluations of public
health interventions see Table 4. We have not tried to be
prescriptive, rather to raise pertinent questions.
Strengths and limitations
This paper is the first to summarise the range of public
health guidance available for the economic evaluation of
public health interventions. We offer a checklist that
highlights issues that need addressing in order to con-
duct economic evaluations of public health interventions
and provide the most up to date summary of guidance
in this field, which has the potential to be of wide benefit
to health economists and other public health services
researchers.
The narrative review methodology was chosen due to
a high level of heterogeneity between each of the guid-
ance documents. A potential limitation of this method is
that it may have resulted in a limited review. However,
we tried to minimise this by expanding our methodology
and exploring the theoretical frameworks underpinning
the guidance and discussing their implications.
Another potential limitation of this review is the lan-
guage restriction placed in the inclusion criteria. The re-
view identified guidance published only in English; this
decision was based upon financial constraints of transla-
tion as the review was unfunded. Additionally, we did not
find any guidance in languages other than English when
conducting an initial scoping search of the literature.
Conclusions
This paper is in no way prescriptive–rather it offers the
first comprehensive source of published guidelines forthose embarking on an economic evaluation of a public
health intervention. The message from our public health
colleagues is very clear–think multidisciplinary. We
argue here that health economics has come, with respect
to public health, full circle from its origins in wider pub-
lic policy. If we approach the evaluation of public health
interventions as “public policy economists”, measuring
health outcomes as part of the full range of outcomes,
rather than trying to stretch the “medical model” with
the limitations of the health economics toolbox, we may
make greater strides to inform public policy to improve
health.
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